DiaMedica Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for DiaMedica Therapeutics (DMAC).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$13Upside to Avg. PT+34.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$12
Nov 14, 2025	Cantor Fitzgerald	Josh Schimmer	Initiate	Overweight	$25
Aug 15, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$12
Jul 18, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$8→$11
Jul 18, 2025	Lake Street	Thomas Flaten	PT Raise	Buy	$11→$14
Jul 18, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$10→$12
May 29, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$10
Mar 19, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$7→$10
Nov 15, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$7
Oct 10, 2024	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$7
Oct 7, 2024	HC Wainwright & Co.	Matthew Caufield	Initiate	Buy	$7
Aug 16, 2024	Oppenheimer	Francois Brisebois	Maintained	Outperform	$6
Apr 24, 2024	Craig-Hallum	Alexander Nowak	Assumes	Buy	$8
Mar 21, 2024	Craig-Hallum	Alexander Nowak	PT Cut	Buy	$11→$8
Mar 21, 2024	Oppenheimer	Francois Brisebois	PT Cut	Outperform	$7→$6

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.

Benzinga Newsdesk

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.

Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11

Craig-Hallum analyst Chase Knickerbocker maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $8 to $11.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14

Lake Street analyst Thomas Flaten maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $11 to $14.

Benzinga Newsdesk

DiaMedica Therapeutics Inc

DiaMedica Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

PRO
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

PRO
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11

PRO
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14

People Also Watch

People Also Watch

DiaMedica Therapeutics Inc

DiaMedica Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

PROCantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25

PROHC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

PROCraig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11

PROLake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

PRO
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25

PRO
HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

PRO
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $11

PRO
Lake Street Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $14